BidaskClub upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research report report published on Saturday morning.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a hold rating to a buy rating and set a $40.00 target price for the company in a research report on Wednesday, January 3rd. Piper Jaffray Companies set a $52.00 price objective on shares of Adamas Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, December 19th. Cowen set a $55.00 price objective on shares of Adamas Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, December 13th. Noble Financial reaffirmed a buy rating on shares of Adamas Pharmaceuticals in a research report on Friday, February 23rd. Finally, Mizuho reaffirmed a buy rating and set a $48.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $45.14.
Shares of Adamas Pharmaceuticals (ADMS) opened at $26.57 on Friday. The firm has a market cap of $708.94, a PE ratio of -5.27 and a beta of 1.59. Adamas Pharmaceuticals has a 1 year low of $13.50 and a 1 year high of $44.00. The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69.
Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its position in shares of Adamas Pharmaceuticals by 13,028.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after buying an additional 135,235 shares during the last quarter. Hikari Power Ltd acquired a new position in Adamas Pharmaceuticals during the 3rd quarter valued at about $635,000. American Century Companies Inc. acquired a new position in Adamas Pharmaceuticals during the 4th quarter valued at about $2,110,000. Prosight Management LP acquired a new position in Adamas Pharmaceuticals during the 4th quarter valued at about $407,000. Finally, EAM Investors LLC acquired a new position in Adamas Pharmaceuticals during the 3rd quarter valued at about $1,795,000. 77.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2018/03/14/adamas-pharmaceuticals-adms-raised-to-hold-at-bidaskclub.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.